BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population in The Green Journal. This is the first prospective NIPT study conducted in an intended-use screening population with near-complete pregnancy outcome ascertainment, providing important new evidence supporting routine use of cfDNA fetal risk assessment in general-risk pregnancies.